ONCAlert | 2018 ASCO Annual Meeting

A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin Lymphoma

Alex Herrera, MD
Published Online: 2:02 AM, Wed December 7, 2016

Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.